BioCentury | Jan 25, 2020
Targets & Mechanisms

CAR T strategies for cracking the code in solid tumors

As drug developers try to crack the code for making CAR T cell therapies work in solid tumors, they aren’t sticking to the playbook that led to success with other modalities. BioCentury’s analysis of the...
BC Extra | Nov 19, 2019
Clinical News

Big gain for Myovant as oral prostate cancer therapy heads for submission

Myovant shares more than doubled in value Tuesday after the company revealed Phase III data showing its oral GnRH receptor antagonist relugolix led to sustained testosterone suppression in 96.7% of prostate cancer patients in Phase...
BC Week In Review | Mar 23, 2018
Clinical News

Mereo's BGS-649 meets in Phase IIb for hypogonadism

Mereo BioPharma Group plc (LSE:MPH) reported top-line data from a Phase IIb trial in 271 obese men with hypogonadotropic hypogonadism showing that all three doses of once-weekly oral BGS-649 met the primary endpoint of normalizing...
BC Innovations | Dec 21, 2017
Translation in Brief

Replacing the replacements

A Wake Forest team has developed a cell-based hormone replacement therapy that can control the hypothalamic-pituitary-ovarian axis with lower levels of estrogen than standard therapies, and could provide a solution to the side effects of...
BC Innovations | Sep 21, 2017
Translation in Brief

Alphamab's soup

Chinese protein engineering company Alphamab is building a one-stop antibody production facility housing a slew of multispecific antibody-generating technologies and its own GMP plant under construction. The company has its own spin on the well-trodden...
BC Week In Review | Jul 28, 2017
Financial News

Facio raises EUR4.8M in venture round

On June 20, facioscapulohumeral muscular dystrophy (FSHD) play Facio Therapies (Leiden, the Netherlands) raised €4.8 million ($5.6 million) in a venture round from Evotec AG (Xetra:EVT), patient organization Amis FSH and FSHD-affected families. Facio Therapies...
BC Extra | May 26, 2017
Clinical News

FSH-blocking antibody could treat osteoporosis, obesity

Researchers at Icahn School of Medicine at Mount Sinai and other institutions showed that an antibody that blocks follicle stimulating hormone (FSH) increased bone mass and decreased body fat in a mouse model of menopause....
BC Week In Review | Mar 9, 2017
Clinical News

BGS-649: Ph IIb ongoing

An IDMC recommended continuation of a double-blind, placebo-controlled, international Phase IIb trial evaluating 3 doses of oral BGS-649 once weekly for 24 weeks based on an interim analysis conducted after the first 93 patients completed...
BC Week In Review | Dec 14, 2016
Clinical News

Rekovelle regulatory update

Ferring Pharmaceuticals A/S , Saint-Prex, Switzerland  Product: Rekovelle follitropin delta (FE 999049)  Business: Genitourinary  Ferring said the European Commission approved an MAA for Rekovelle follitropin delta for use in controlled ovarian stimulation to develop multiple follicles...
BC Week In Review | Oct 31, 2016
Clinical News

KN015: Phase I started

Alphamab began an open-label, placebo-controlled, Chinese Phase I trial to evaluate a single dose of subcutaneous KN015 in about 70 healthy volunteers. Suzhou Alphamab Co. Ltd. , Suzhou, China  Product: KN015   Business: Endocrine/Metabolic  Molecular target:...
Items per page:
1 - 10 of 151